Browse the evidence

Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.

Semaglutide 2.4 mg, taken as a weekly injection, is a highly effective treatment for obesity, leading to an average 14.9% weight loss over 68 weeks. It works by mimicking the GLP-1 hormone to increase satiety and reduce appetite. Common side effects include gastrointestinal issues like nausea and diarrhea.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.

Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.

Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.

If you are struggling to lose weight with Semaglutide, ask your doctor about Tirzepatide. Clinical trials show it can lead to greater weight loss (around 21%) compared to Semaglutide (around 14%) in obese patients without diabetes. However, be aware that it may be more expensive and less likely to be covered by insurance.

GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.

Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.

Tirzepatide is a once-weekly injection approved for T2DM and obesity. It works by mimicking hormones that regulate blood sugar and appetite. Clinical trials show it lowers HbA1c by up to 2.5% and causes significant weight loss (15-25%). It is more effective than semaglutide and insulin for these metrics. Common side effects are gastrointestinal (nausea, diarrhea) but often improve over time. Weight regain is common if the drug is stopped, suggesting long-term use may be necessary for sustained results.

Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.

If your primary goal is maximum weight loss and you do not have diabetes, tirzepatide (15mg weekly) is clinically superior to semaglutide (2.4mg weekly). While both are effective, tirzepatide yields significantly greater fat loss and waist reduction. Be aware that while tirzepatide may have better GI tolerability, it still carries class-specific risks.

Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.

If you stop taking incretin-based weight loss medication, you will likely regain about two-thirds of the weight you lost within a year. This is not a failure of willpower but a biological response to the loss of the drug's hormonal effects. To maintain your weight loss, you likely need to continue the medication long-term or use very aggressive, sustained lifestyle interventions, though even those are often insufficient to prevent significant regain.

GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.

GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.

mTORC1 is the central integrator of anabolic signals from both resistance exercise and dietary protein, mediating muscle protein synthesis and hypertrophy.

Understanding mTORC1 is important for researchers but has limited direct practical application for the average person. Focus on the external drivers: lift weights and eat enough protein.

Metformin reduces the risk of progression from prediabetes to type 2 diabetes by 31% and is recommended for specific high-risk subgroups (age 25-59, BMI ≥35, FPG ≥6.1 mmol/L, or history of gestational diabetes).

If lifestyle changes alone are not enough, your doctor may prescribe metformin. It is typically started at a low dose (500 mg) and increased to 1,500 mg daily to minimize stomach issues. Use the extended-release version if possible. Monitor your blood sugar every 6 months. This is particularly recommended if you are younger, have a higher BMI, or have a history of gestational diabetes.

Second-generation obesity management medications (semaglutide and tirzepatide) produce 15-20% body weight loss, significantly exceeding the 5-10% typically achieved by lifestyle interventions alone.

Second-generation obesity medications like semaglutide and tirzepatide are significantly more effective for weight loss than lifestyle changes alone, achieving 15-20% body weight reduction. They work by targeting hormonal pathways that regulate appetite and metabolism, addressing the biological drivers of obesity rather than relying solely on willpower.

Discontinuation of second-generation OMMs leads to significant weight regain, highlighting the chronic nature of obesity and the need for long-term management or intensive lifestyle support upon discontinuation.

Stopping OMMs typically leads to significant weight regain. If you choose to discontinue, work with your healthcare provider to intensify lifestyle interventions, including dietary strategies and physical activity, to help maintain your weight loss.

Combining basal insulin with a GLP-1 receptor agonist (GLP-1RA) significantly reduces HbA1c, body weight, and hypoglycemia risk compared to basal insulin alone or intensified insulin regimens.

If you are on basal insulin and your blood sugar is still high, ask your doctor about adding a GLP-1 receptor agonist (like liraglutide or dulaglutide). This combination lowers blood sugar more effectively than increasing insulin alone, helps you lose weight, and reduces the risk of low blood sugar episodes.

Pharmacotherapy (Orlistat, Lorcaserin, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide) adds 2.5 to 8.9 kg of mean weight loss compared to placebo when used as an adjunct to lifestyle intervention.

If lifestyle changes alone aren't enough, FDA-approved medications can help. These drugs work by reducing hunger or blocking fat absorption. They are meant for long-term use, not quick fixes. Consult a doctor to see if you are a candidate based on your BMI and health history.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity regardless of baseline characteristics such as age, race, or baseline BMI, although females and those with lower baseline body weight experience greater magnitude of loss.

Semaglutide 2.4mg weekly, combined with lifestyle changes, is effective for weight loss across diverse demographics. While women and those starting at a lower weight may lose more, men and those with higher starting weights still achieve significant, clinically meaningful weight reduction. Do not skip treatment based on demographics.

Once-weekly subcutaneous semaglutide 2.4 mg combined with lifestyle intervention induces significant weight loss and improves cardiometabolic risk factors in adults with overweight/obesity and type 2 diabetes.

If you have type 2 diabetes and are overweight, adding once-weekly semaglutide 2.4 mg to your diet and exercise routine can lead to significantly more weight loss (about 10% of body weight on average) and better blood sugar control than diet and exercise alone. While you may experience temporary stomach issues, the long-term health benefits are substantial.

Once-weekly subcutaneous semaglutide 2.4 mg combined with lifestyle intervention induces a mean body weight loss of approximately 15% (14.9%) over 68 weeks in adults with overweight or obesity, significantly outperforming placebo.

If you have a BMI of 30 or higher (or 27 or higher with a weight-related health issue), adding once-weekly semaglutide 2.4 mg to your lifestyle changes can help you lose about 15% of your body weight over 16 months. This is significantly more than lifestyle changes alone. Be prepared for possible mild, temporary stomach issues, but the weight loss benefits are substantial and come with improvements in blood pressure and blood sugar.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant weight loss in adults with overweight or obesity, with efficacy largely independent of baseline characteristics such as age, race, BMI, and glycemic status, though females and those with lower baseline body weight experience greater magnitude of loss.

If you have obesity or overweight, once-weekly semaglutide (2.4 mg) is a highly effective treatment for weight loss, regardless of your age, race, or starting weight. However, be aware that women and those with a lower starting body weight tend to lose more weight than men or those with a higher starting body weight. This treatment is used alongside lifestyle changes.

Once-daily subcutaneous liraglutide (2.4–3.0 mg) combined with a 500 kcal/day caloric deficit and exercise counseling sustains significant weight loss (7.8 kg) and improves cardiovascular risk factors (blood pressure, lipids, prediabetes) over a 2-year period in obese non-diabetic adults.

If you are obese and have not been able to lose weight through diet and exercise alone, adding once-daily liraglutide (2.4-3.0 mg) to a moderate caloric deficit (500 kcal/day) and exercise can help you sustain significant weight loss (around 8 kg) and improve your blood pressure and cholesterol over two years. Expect some initial nausea, which usually subsides, and be prepared for daily injections.

Lorcaserin (10 mg once or twice daily) produces significant weight loss and improved glycemic control in patients with type 2 diabetes compared to placebo.

If you have Type 2 Diabetes and struggle with weight, lorcaserin (taken as a 10mg pill once or twice daily) can help you lose about 5% of your body weight over a year, which is significantly more than placebo. It also helps lower your blood sugar (HbA1c). This works best when combined with standard lifestyle changes like eating 600 calories less per day and exercising moderately for 30 minutes a day. Common side effects include nausea and headache, but severe low blood sugar was not observed in this study.

High-calorie-expenditure exercise improves cardiometabolic risk factors (insulin resistance, lipid profiles, blood pressure) more effectively than standard exercise in overweight coronary patients, independent of medication use.

Improving your heart health isn't just about taking medication; it's about improving how your body handles insulin and fat. By increasing your weekly exercise calorie burn to 3000-3500 kcal (e.g., through frequent walking), you can significantly improve your insulin sensitivity and lipid profile, reducing your risk of metabolic syndrome and future cardiac events.

Tirzepatide (5-15 mg weekly) produces superior weight loss (10.7-20.9%) compared to placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidities) via dual GIP/GLP-1 receptor agonism.

Tirzepatide is a once-weekly injection that significantly reduces body weight (up to 20%+) in obese adults. It works by mimicking gut hormones to suppress appetite and slow digestion. Start with the lowest dose and increase gradually to minimize stomach upset. Combine with a 500-calorie daily deficit and 150 minutes of weekly exercise for best results.

Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.

For adults with obesity or overweight, once-weekly semaglutide (titrated up to 2.4 mg) combined with lifestyle changes is a highly effective medical intervention for significant weight loss, outperforming lifestyle changes alone. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically lead to stopping treatment.

Once-weekly semaglutide improves cardiometabolic markers including HbA1c, fasting plasma glucose, blood pressure, and lipid profiles in overweight/obese patients, independent of or alongside weight loss.

Beyond weight loss, semaglutide helps improve blood sugar control (HbA1c), blood pressure, and lipid profiles in overweight/obese individuals, offering broader cardiovascular protection.